"Awaiting clarity on more funding to promote pharma R&D": Kotak Securities

03 February 2023 | Views

Purvi Shah, Deputy Vice President - Fundamental Research, Kotak Securities shares her reaction on Union Budget 2023-24

"Allocation for development of pharma industry has been increased from Rs 100 crore in FY23E to Rs 1250 crore in FY24E. Impact of this will be that there will be new programmes to promote pharma R&D through centres of excellence. However, we would await clarity on where exactly these additional funds are going to be used."


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account